金城医药(300233) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥608,977,257.17, a decrease of 6.41% compared to ¥650,685,404.33 in the same period last year[8]. - Net profit attributable to shareholders was ¥50,855,115.49, down 49.66% from ¥101,030,988.13 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥40,499,938.16, a decline of 59.32% from ¥99,564,127.60 in the previous year[8]. - Basic and diluted earnings per share were both ¥0.13, down 50.00% from ¥0.26 year-on-year[8]. - The weighted average return on net assets was 1.47%, a decrease of 0.98% from 2.45% in the previous year[8]. - The company reported a revenue of 608.98 million yuan, a year-on-year decrease of 6.41%[24]. - The net profit attributable to shareholders was 50.86 million yuan, down 49.66% year-on-year, primarily due to weakened demand from downstream customers in the pharmaceutical intermediate sector affected by the pandemic[24]. - The company reported a net profit of ¥584,151,634.40, up from ¥533,296,518.91, indicating a growth of approximately 9.56% in retained earnings[61]. - Total comprehensive income amounted to CNY 52,846,955.50, a decrease from CNY 101,584,922.00 in the previous period[77]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥7,144,592.39, a significant drop of 91.33% compared to ¥82,376,320.62 in the same period last year[8]. - Cash and cash equivalents increased to ¥1,079,948,808.21 from ¥1,074,969,550.07, showing a slight growth[52]. - The total cash and cash equivalents at the end of the period amounted to 851,540,955.63, down from 1,001,465,378.99 in the previous period, reflecting a decrease of approximately 14.94%[91]. - The net cash flow from operating activities was -10,352,951.45, slightly improved from -10,817,347.95 in the previous period[92]. - Cash inflows from operating activities totaled 4,821,000.56, an increase from 4,295,191.39 in the previous period[92]. - The net cash flow from financing activities was 73,393,829.77, compared to a negative cash flow of -19,585,031.96 in the previous period, indicating a significant improvement[91]. - The cash flow from financing activities showed a net inflow of 326,770,625.00, compared to 85,771,719.99 in the previous period, marking a substantial increase[95]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,056,843,328.48, an increase of 1.13% from ¥5,000,113,119.10 at the end of the previous year[8]. - Total current assets amounted to ¥2,186,571,091.82, a decrease of 1.58% from ¥2,221,848,961.83 on December 31, 2020[52]. - Total liabilities slightly increased to ¥1,535,255,546.80 from ¥1,532,815,590.71, showing a marginal rise[58]. - The total equity attributable to shareholders rose to ¥3,490,279,422.15 from ¥3,437,981,008.87, an increase of about 1.52%[61]. - Total liabilities reached CNY 203,529,431.12, with current liabilities at CNY 155,732,903.31 and non-current liabilities at CNY 47,796,527.81[103]. Expenses - Research and development expenses rose by 70.24% to RMB 40.37 million, driven by increased investment in R&D projects[21]. - Sales expenses increased by 37.70% to RMB 161.34 million, attributed to enhanced market and brand promotion efforts[21]. - Management expenses rose to CNY 10,823,033.91 from CNY 7,559,057.10 in the previous period, indicating higher administrative costs[78]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,477[12]. - The largest shareholder, Zibo Jincheng Investment Co., Ltd., held 20.13% of the shares, totaling 78,552,154 shares[13]. Market Conditions - The ongoing pandemic continues to pose significant uncertainty for the company's export business, particularly affecting sales to India[24]. - The company is closely monitoring the pandemic's developments and their impact on export operations[24]. Other Financial Metrics - The company's tax payable decreased by 69.84% to RMB 14.63 million, primarily due to a decline in VAT and corporate income tax[21]. - The company's inventory shares decreased by 45.61% to RMB 40.01 million, resulting from the cancellation of repurchased shares[21]. - The company reported a 262.41% increase in other income to RMB 14.98 million, largely due to government subsidies received[21]. - The company's investment income decreased by 133.42% to a loss of RMB 221,822.67, attributed to increased losses from external investments[21].